Interview, Fireside Chat
Dr. Arie Belldegrun, Co-Founder and Executive Chairman, Allogene Therapeutics
- Dr. Ari Beldergren holds dual training from Hebrew University (clinical medicine) and the Weizmann Institute (Ph.D. in immunology), establishing a foundation in both patient care and scientific research.
- At the NIH, his research shifted from suppressing T-cells for organ transplant rejection to stimulating them for cancer treatment, leading to the world's first adoptive cell therapy trials under the mentorship of Steve Rosenberg.
- Beldergren identifies the "physician-scientist" model as the most demanding career path but notes it offers the highest potential for academic advancement due to its dual focus on clinical practice and laboratory innovation.
- In 2009, driven by the progress of the Human Genome Project, Beldergren and partner Owen Weedy co-founded Kite Pharma to commercialize academic immunotherapy technologies that were previously shelved at universities.
- Kite Pharma secured a Cooperative Research and Development Agreement (CRADA) with the NIH after a 1.5-year negotiation process to license Rosenberg's engineered T-cell technology.
- Prior to Kite's involvement, major pharmaceutical companies and biotechs rejected T-cell therapy, citing the complexity of "living drugs" (engineered cells) compared to traditional vial-based pills.
- In 2014, David (a leader from Amgen) joined Kite Pharma after witnessing patient outcomes where terminal cancer cases achieved complete remission in three to four weeks with a single treatment.
- Kite Pharma's CAR T-cell technology demonstrated the ability to eliminate cancer in patients with failing immune systems who had exhausted all other treatment options.
- Beldergren defines success solely by whether a drug improves patient lives, citing Kite's impact on lymphoma, Amgen's future bladder cancer drug, and Cougar's prostate cancer drug as key achievements.
- The engineered T-cell field has expanded from one or two pioneering companies at its inception to approximately 300 companies currently active in the sector.
- Beldergren projects continued growth in the immunotherapy sector, emphasizing that the primary metric for the industry's value is the number of lives saved or significantly improved.